Research & Development
Sepsis: Page 2
Sepsis increases heart failure, rehospitalization risks following hospital discharge
Hospital patients who initially had or developed sepsis were at higher risk for heart failure, rehospitalization, or death within 12 years than patients without sepsis.
February 1, 2023
Vision Research supplies high-speed camera for Cytovale point-of-care sepsis test
An enabling technology for flow cytometry, the Vision Research Phantom VEO 710 high-speed camera resolves blood cells as they move through a microfluidics channel at three meters per second.
January 30, 2023
Asep Medical inks joint venture term sheet with Sansure Biotech, preps sepsis test for launch in China
As part of the agreement, Sansure will invest in the joint venture. Asep Medical will provide a sublicense to patent rights to its Sepset sepsis test for the Chinese marketplace and would receive a royalty when the test is marketed.
January 30, 2023
T2 Biosystems nabs contract extension with group purchasing organization
Products covered under the contract with Vizient, a purchasing organization for healthcare institutions, include the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel. All detect sepsis-causing bacterial and fungal pathogens from whole blood.
December 28, 2022
DeepUll obtains 20-million-euro loan to develop point-of-care sepsis test
DeepUll’s sepsis testing product is being developed to detect more than 250 different pathogens and approximately 15 resistance genes in one hour from 10 mL of whole blood.
December 13, 2022
Blu Biotech collaborates with University of Michigan on breath biomarkers for sepsis and ARDS detection
ARDS and sepsis are life-threatening and can be difficult to detect early. Blu Biotech, University of Michigan, and the Weil Institute seek to change that with the development of biomarkers for both conditions.
November 16, 2022
At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time
The firm obtained FDA 510(k) clearance for its SeptiCyte Rapid test last year. The test runs on the sample-to-answer Biocartis Idylla molecular testing platform.
November 5, 2022
Biocartis to present 9 abstracts on MDx platform, assays at AMP 2022
One study evaluates the performance of the Immunexpress SeptiCyte Rapid ethylenediamine tetraacetic acid blood-compatible cartridges on the Idylla platform.
October 31, 2022
Avails Medical nabs $1.7M to develop AST test
The money will be used to further develop the fully electrical Avails Medical eAST system, which provides a time-to-results average of five hours. The system will enable healthcare providers to determine the most effective antibiotic treatment for patients with severe bloodstream infections, such as sepsis, particularly those involving multidrug-resistant pathogens.
August 31, 2022
Immunexpress adds undiluted EDTA to blood samples
SeptiCyte Rapid is a sample-to-answer, cartridge-based, molecular test for sepsis that uses reverse transcription polymerase chain reaction (RT-PCR) to quantify the relative expression levels of host response genes isolated from whole blood.
August 22, 2022
Accelerate Diagnostics prices $35M stock offering
Its gross proceeds from the offering, before deductions, are expected to be $35 million, said Accelerate, a Tucson, AZ-based developer and supplier of identification and antimicrobial susceptibility tests (ID/AST) for bloodstream infections including sepsis.
August 18, 2022
VolitionRx inks research deal with MD Anderson
Financial and other terms of the agreement were not disclosed.
August 10, 2022
Page 2 of 5